公开(公告)号：US09173855B2

公开(公告)日：2015-11-03

申请号：US13882565

申请日：2011-11-02

申请人： Hiroko Udagawa ,  Yoshikazu Inaba ,  Yukihiko Noda ,  Kumi Obata ,  Hiroto Terashima

发明人： Hiroko Udagawa ,  Yoshikazu Inaba ,  Yukihiko Noda ,  Kumi Obata ,  Hiroto Terashima

IPC分类号： A61F13/00 ,  A61K31/415 ,  A61F13/02 ,  A61K9/70 ,  A61K31/4168

CPC分类号： A61K9/7053 ,  A61K9/7023 ,  A61K9/7046 ,  A61K31/4168

摘要： Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine. The weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] is 0.1 to 2.0.

摘要翻译： 公开了一种贴剂，其是包含沉积的可乐定晶体的制剂，并且即使在变化的温度下储存后也能提供稳定的经皮吸收能力。 所公开的贴剂包括一体地叠置在背衬的一个表面上的背衬和药物层。 含药层含有5〜30重量％的可乐定，包括结晶状态下的可乐定; 25〜90重量％的粘均分子量为80万以上的高分子基（A） 和5〜60重量％的能够溶解可乐定的液体添加剂。 液体添加剂与大分子基质（A）[液体添加剂/大分子基（A）]的重量比为0.1〜2.0。

公开(公告)号：US20130261572A1

公开(公告)日：2013-10-03

申请号：US13882565

申请日：2011-11-02

申请人： Hiroko Udagawa ,  Yoshikazu Inaba ,  Yukihiko Noda ,  Kumi Obata ,  Hiroto Terashima

发明人： Hiroko Udagawa ,  Yoshikazu Inaba ,  Yukihiko Noda ,  Kumi Obata ,  Hiroto Terashima

IPC分类号： A61K9/70 ,  A61K31/4168

CPC分类号： A61K9/7053 ,  A61K9/7023 ,  A61K9/7046 ,  A61K31/4168

摘要： Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine. The weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] is 0.1 to 2.0.

摘要翻译： 公开了一种贴剂，其是包含沉积的可乐定晶体的制剂，并且即使在变化的温度下储存后也能提供稳定的经皮吸收能力。 所公开的贴剂包括一体地叠置在背衬的一个表面上的背衬和药物层。 含药层含有5〜30重量％的可乐定，包括结晶状态下的可乐定; 25〜90重量％的粘均分子量为80万以上的高分子基（A） 和5〜60重量％的能够溶解可乐定的液体添加剂。 液体添加剂与大分子基质（A）[液体添加剂/大分子基（A）]的重量比为0.1〜2.0。